FDA Approves First Generic Versions of FARXIGA - Takeaways - MDSpire

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

  • By

  • Kathryn Wighton

  • April 7, 2026

  • 2 min

Share

  • 1

    The FDA approved the first generic versions of FARXIGA (dapagliflozin) for adults with type 2 diabetes and cardiovascular risks.

  • 2

    Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that helps reduce glucose and sodium reabsorption in the kidneys.

  • 3

    The generic tablets have the same prescribing information, contraindications, warnings, and precautions as the branded product.

  • 4

    Common safety concerns include diabetic ketoacidosis and infections, with adverse events like genital infections and urinary tract infections reported.

  • 5

    Healthcare providers should consult the Orange Book for approved products and review full prescribing information for safety guidance.

Original Source(s)

FDA Approves First Generic Versions of FARXIGA

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.